Rutaecarpine attenuates osteoclastogenesis by impairing macrophage colony stimulating factor and receptor activator of nuclear factor κ-B ligand-stimulated signalling pathways

Yutaka Fukuma, Eiko Sakai, Shunsuke Komaki, Kazuhisa Nishishita, Kuniaki Okamoto, Takayuki Tsukuba

Research output: Contribution to journalLetter

1 Citation (Scopus)

Abstract

Rutaecarpine is a major alkaloid isolated from Evodia rutaecarpa. Here, we investigated the effects of rutaecarpine on osteoclast differentiation induced by macrophage colony stimulating factor (M-CSF) and receptor activator of nuclear factor κ-B ligand (RANKL) in bone marrow-derived macrophages (BMMs). Treatment with rutaecarpine significantly inhibited osteoclastogenesis and prevented bone resorption of BMM-derived osteoclasts. Mechanistically, rutaecarpine decreased the protein level of nuclear factor of activated T cells cytoplasmic-1 (NFATc1) and the phosphorylation of other signalling pathways during the osteoclast differentiation. Thus, rutaecarpine may be useful as a therapeutic agent for the treatment of bone diseases.

Original languageEnglish
Pages (from-to)863-865
Number of pages3
JournalClinical and Experimental Pharmacology and Physiology
Volume45
Issue number8
DOIs
Publication statusPublished - Aug 2018

Keywords

  • bone marrow-derived macrophages
  • osteoclast differentiation
  • rutaecarpine

ASJC Scopus subject areas

  • Physiology
  • Pharmacology
  • Physiology (medical)

Fingerprint Dive into the research topics of 'Rutaecarpine attenuates osteoclastogenesis by impairing macrophage colony stimulating factor and receptor activator of nuclear factor κ-B ligand-stimulated signalling pathways'. Together they form a unique fingerprint.

  • Cite this